Establishment of mouse model of inherited PIGO deficiency and therapeutic potential of AAV-based gene therapy

Ryoko Kuwayama1,2, Keiichiro Suzuki3,4,5, Jun Nakamura3, Emi Aizawa4, Yoshichika Yoshioka3,6,7, Masahito Ikawa8, Shin Nabatame2, Ken-ichi Inoue9, Yoshiari Shimmyo10, Keiichi Ozono2, Taroh Kinoshita1,11 & Yoshiko Murakami1

Inherited glycosylphosphatidylinositol (GPI) deficiency (IGD) is caused by mutations in GPI biosynthesis genes. The mechanisms of its systemic, especially neurological, symptoms are not clarified and fundamental therapy has not been established. Here, we report establishment of mouse models of IGD caused by PIGO mutations as well as development of effective gene therapy. As the clinical manifestations of IGD are systemic and lifelong lasting, we treated the mice with adeno-associated virus for homology-independent knock-in as well as extra-chromosomal expression of Pigo cDNA. Significant amelioration of neuronal phenotypes and growth defect was achieved, opening a new avenue for curing IGDs.
Over 150 kinds of glycosylphosphatidylinositol (GPI)-anchored protein (GPI-AP) are expressed on the surface of mammalian cells. GPI-APs have a variety of roles, including acting as hydrolytic enzymes, adhesion molecules, receptors, protease inhibitors, and complement regulatory proteins. At least 27 genes are involved in the biosynthesis and transport of GPI-APs, and mutations in these genes cause inherited GPI deficiency (IGD). IGD is a recessive hereditary disease, which mainly features neurological abnormalities. Recently, many individuals with IGD possessing PIGO mutations have been reported, and they show a wide range of symptoms, such as hyperphosphatasia, intellectual disability, developmental delay, epilepsy, and organ anomalies. PIGO is a transfectase that adds ethanolamine phosphate (EtNP) to the third mannose, thereby attaching GPI to proteins. Defects in PIGO thus cause decreased expression of various GPI-APs. As the complete loss of GPI biosynthesis causes early embryonic death, most individuals with IGDs exhibit partial deficiency in GPI biosynthesis. There is no animal model mimicking IGD individuals and the mechanism behind the neurological manifestations has not been clarified. In addition, there are no fundamental therapeutic interventions.

To obtain a better understanding of the pathogenic mechanism of IGD and to test potential therapeutic interventions, we here report three lines of Pigo knock-in (KI) mice bearing three mutations homologous to PIGO mutations found in IGD individuals with mild to severe symptoms. The severest line of mice recapitulated the neurological phenotypes of PIGO deficiency.

Adeno-associated virus (AAV) vector-mediated gene delivery has undergone several trials and been used clinically to treat intractable monogenic diseases. As IGD is associated with defects in normal neurological development, therapy should be initiated at a young age and the therapeutic effect should be maintained for many years. As for recombinant AAV (rAAV)-mediated gene transfer, rAAV persisting as an extra-chromosomal form in the nucleus of transduced cells is diluted through repeated cell divisions, leading to the loss of transgene expression. Furthermore, as PIGO shares a stabilizing component, PIGF, with another transfectase PIGG that adds EtNP to the second mannose, overexpression of PIGO would have a harmful effect through the decreased expression of PIGG. A genome-editing strategy using the CRISPR-Cas9 system enables us to overcome these limitations of overexpression-based gene therapy. A conventional homology-directed repair (HDR)-mediated integration method is not efficient enough for effective treatment because of its poor accessibility to nondividing cells.

Recently, one of us developed a nonhomologous end joining (NHEJ)-based homology-independent strategy for targeted transgene integration (HITI), which allows more robust gene knock-in in both dividing and nondividing cells than for HDR. However, the current version of HITI is still insufficient to cure many inherited diseases due to the low frequency of transgene insertion. To overcome this limitation and optimize the treatment for IGD, we developed a novel gene-therapy method, homology-independent targeted integration assisted with a low level of transgene expression (HITI-TE). HITI-TE is a combinational approach involving HITI-mediated Pigo full-coding cDNA insertion at the Pigo locus and Pigo full-coding cDNA expression driven by a weak promoter encoded in the ITR region of the AAV vector. Using the HITI-TE method in disease model mice, we show the clear amelioration of various symptoms of IGD.

Results

Partial loss-of-function mutants of Pigo with different severities. As clinical severity varies among those affected by IGD depending on the residual GPI biosynthetic activities of mutant alleles, we aimed to generate mouse lines exhibiting conditions with different levels of severity. To achieve this, we chose three missense mutants of the PIGO gene, p.Arg119Trp (R119W), pThr130Asn (T130N), and p.Lys1047Ile (K1047E), found in individuals with IGD having different clinical severities and generated the homologous mouse Pigo mutant cDNAs p.R119W, p.T130N, and p.K1051E, respectively. We first analyzed the activities of the three Pigo mutants. Pigo-knockout (KO) Neuro2a cells generated by the CRISPR-Cas9 system were transfected with each mutant Pigo cDNA and analyzed by flow cytometry. The three missense mutant cDNAs rescued the surface expression of GPI-AP with reduced efficiency compared with the wild-type cDNA (Supplementary Fig. 1a). Protein expressions of Pigo mutants were comparable to the wild-type level (Supplementary Fig. 1b). Based on the percentage of GPI-AP-rescued cells, we concluded that T130N was the severest mutation, R119W and K1051E were milder. We next introduced these missense mutations into mouse embryonic stem (ES) cells by CRISPR-Cas9-mediated knock-in (Supplementary Fig. 2) and generated three Pigo-KI mouse lines, termed the A-, B-, and C-lines, for R119W, T130N, and K1051E, respectively (Fig. 1a-c and Supplementary Fig. 3). We also called the three mutant alleles R119W, T130N, and K1051E, alleles a, b, and c, respectively. During R119W KI procedures in ES cells, we obtained an ES clone having a KO allele and generated a Pigo-KO mouse line (Fig. 1d). By crossing each heterozygous Pigo KI mouse, Pigoa/b−/+, Pigob/b−/+, and Pigoc/b−/+, with a heterozygous KO mouse, Pigo+/−, we obtained knock-in/knockout (KIKO) mice, Pigoa/b−/−, Pigob/b−/−, and Pigoc/b−/− (Fig. 1e), which mimicked the genotype of IGD individuals with compound heterozygous bi-allelic PIGO mutations.

Decreased expression of GPI-APs in Pigo B-line KI mice and KIKO mice. Using the Pigo B-line mice with the severest mutation, we tested the expression of GPI-APs. Flow cytometric analysis of blood granulocytes indicated that the surface expression levels of Gr-1 in the homozygous Pigo B-line KI mouse (termed Pigoa/b−/−) were decreased compared with those of their wild-type controls (79.1% of the control, p < 0.001). Pigo B-line knock-in/knockout (KIKO) mice (termed Pigoa/b−/−) showed lower levels of Gr-1 than Pigoa/b−/− mice (66.0% of the control, p < 0.001) (Fig. 1f). These results were compatible with previous reports describing that patients with PIGO deficiency showed lower levels of GPI-APs in blood granulocytes.

To determine whether the expression of GPI-APs in the brain is reduced, the brain lysates of the Pigoa/b−/− mouse and its wild-type littermates were analyzed for Thy1 and contactin1, GPI-APs, by western blotting. The expression of Thy1 in the Pigoa/b−/− mouse cerebrum was decreased to about 50% of that of the control, whereas the expression of contactin1 was not significantly decreased (Supplementary Fig. 4). Additionally, we found that myelin basic protein (MBP), a major, non-GPI-anchored protein of myelin, was decreased in Pigoa/b−/− mouse cerebrum and cerebellum to approximately 70% of control levels, suggesting that myelination is affected in the Pigoa/b−/− mouse (Supplementary Fig. 4).

Hyperphosphatasia seen in PIGO-IGD was reproduced in Pigo KIKO mice. The plasma alkaline phosphatase (ALP) level was higher in homozygous Pigoa/b−/− mice than in their wild-type controls (p < 0.05). Pigoa/b−/− mice showed even more elevated levels of plasma ALP than their wild-type controls (p < 0.001) (Fig. 1g). As hyperphosphatasia in IGD with PIGO deficiency is caused by secretion of the processed precursor protein of ALP without GPI anchoring, its reproduction in these Pigoa/b−/− and Pigob/b−/− mice indicated that GPI biosynthesis was impaired.
Growth defect, decreased survival, and tremor in Pigo KI and KO mice. We followed the growth of the three lines of Pigo homozygous KI and KIKO mice in comparison with that of their littermate heterozygous and wild-type mice by measuring the body weight. The weight of Pigob/b mice was similar to that of the controls at birth, but from around 4 weeks of age, their growth gradually slowed down, and their weight were significantly lower than Pigob/+ and Pigob+/+ at 5–6 weeks of age (p < 0.05). Their growth ceased at around 7–8 weeks, and their weight gradually decreased after 14 weeks (Fig. 2a).

Pigob/− mice had stronger growth defects, and they were significantly smaller than Pigob/+ or Pigob+/− and Pigob+/+ at 4 weeks of age (p < 0.05) (Fig. 2b). In contrast, the growth of Pig homoyzygous KI mice of A- and C-lines (Pigoαα and Pigocα), and that of their KIKO (Pigoα− and Pigoα−) mice were comparable to the levels of their heterozygous and wild-type littermate controls (Fig. 2a, b). Life spans of Pigob/b mouse (median survival, approximately 40 weeks) and Pigob/+ mice (median survival, approximately 15 weeks) were clearly shorter than those of their wild-type controls (100% survival at 36 weeks of age), whereas most Pigoαα, Pigoα−, Pigoα−, and Pigoα− survived for more than 36 weeks, which was not so different from the findings of their littermate controls (Fig. 2c).

Tremor occurred in Pigob/b mice without exception at around 6 weeks, while it started a week earlier (at 5 weeks) in Pigob/− mice (Fig. 2d and Supplementary Movie 1 and 2). In A- and C-lines, homozygous KI mice never showed tremor, but almost all Pigob/− mice started tremor at 7–16 weeks of age. Pigoc/− mice did not exhibit tremor (Fig. 2d).
mice displayed hindlimb clasping at around 12 weeks of age (Fig. 4e) and they started to exhibit an ataxic gate with dragging of the hindlegs (Supplementary Movie 3).

**The Pigo KI mice were more susceptible to seizures.** We analyzed the 24-h EEG record with video of Pigo KI mice and wild-type controls (n = 3, each group) (Fig. 2e). Pigoa/a and Pigoa/b mice exhibited slow waves in the 3–4-Hz range compared with the 6–7-Hz activity in wild-type controls, whereas two out of three Pigoa/c mice showed those in the 3–4-Hz range. Fast Fourier transform (FFT) power spectral analysis of 8-h recorded EEG in the dark phase showed that all three lines of Pigo KI mice showed high power in delta waves (0.75–4 Hz), indicating that slow waves...
with high amplitude were dominant throughout the dark phase. In wild-type mice, such peaks in slow waves could not be seen (Supplementary Fig. 5a). Pigo\textsuperscript{a/a} and Pigo\textsuperscript{b/b} mice displayed interictal epileptiform discharges such as spikes and sharp waves (Fig. 2e). These were consistent with the slow background activities with sharp waves that were previously observed in individuals with PIGO IGD\textsuperscript{22,36}.

During video observation, myoclonic seizures with epileptic discharges were displayed in Pigo\textsuperscript{a/a} and Pigo\textsuperscript{b/b} mice, and clonic seizures, a more severe type, were seen only in Pigo\textsuperscript{b/b} mice. No spontaneous seizures were seen in Pigo\textsuperscript{c/c} mice nor in wild-type mice. To assess the susceptibility of the mutant lines to seizures, we confirmed the presence of acute PTZ-induced seizures using scoring new PTZ scale (Supplementary Table 1) by referring to Modi and colleagues\textsuperscript{37}.

After the administration of low doses of PTZ (20 mg/kg), all Pigo\textsuperscript{b/b} mice displayed severe myoclonic jerk or clonic seizures (score 3–6) accompanied by electrographic activity such as spike and wave complex (Fig. 2e). In contrast, one out of three Pigo\textsuperscript{a/a} mice showed myoclonic jerk (score 2–3). Pigo\textsuperscript{c/c} mice showed only epileptic discharges in EEG, without behavioral manifestation of seizures (score 1) (Fig. 2e).

**Magnetic resonance imaging (MRI) analysis of mouse brain.**

Brains of Pigo\textsuperscript{b/b} mice and littermate Pigo\textsuperscript{b/c} mice were analyzed by MRI. No mice showed any difference in the contrast in T2-weighted images (Fig. 2f). The corpus callosum and anterior commissure were thinner in Pigo\textsuperscript{b/b} male mice than in the controls (Fig. 2f). Pigo\textsuperscript{b/b} mice showed a decreased volume of skeletal muscle in the head (82% of control) (Supplementary Fig. 6a). It appears that the decreased muscle volume accounted for the decreased body weight in Pigo\textsuperscript{b/b} mice (Supplementary Fig. 6b). The volumes of the cerebellum were slightly decreased in Pigo\textsuperscript{b/b} mice (90% of control), whereas those of the cerebrum were not (Fig. 2f and Supplementary Fig. 6c). In addition, the pituitary glands were small in Pigo\textsuperscript{b/b} mice (Fig. 2f and Supplementary Fig. 6d). Source data are provided as a Source Data file.

**Histological analysis of the brain.** To analyze the more details of the brain tissue, Nissl and immunohistochemical staining of brain sections were performed. Nissl staining, which stains the neuronal cell body, showed no abnormalities in the Pigo\textsuperscript{b/b} mouse including Purkinje cells in the cerebellum (Supplementary Fig. 7a). Immunohistochemical staining of the brain sections of Pigo\textsuperscript{b/b} mouse showed no abnormalities including the number of oligodendroglia, astrocytes and synapses (Supplementary Fig. 7b–d). We did not find clear difference in MBP staining (Supplementary Fig. 7b) in spite that MBP of the Pigo\textsuperscript{b/b} mouse brain was decreased to 70% of wild-type mice by western blotting (Supplementary Fig. 4). A small decrease might not be detected by immunohistochemical staining. Primary culture of neurons from Pigo\textsuperscript{b/b} fetal brain revealed that the cells had defect in attachment to the dish, however, after attachment, they developed normally (Supplementary Fig. 8a, b). FACS analysis of the established embryonic fibroblasts from Pigo\textsuperscript{b/b} mouse also showed that GPI-AP stained by FLAER was not decreased compared to the controls (Supplementary Fig. 8c).

**Animal behavioral analysis.** Pigo B-line Pigo\textsuperscript{b/b} and Pigo\textsuperscript{b/c} mice were small compared to wild-type controls. They had severe tremors and apparent motor dysfunction. So, we thought that they are not suitable for comprehensive behavioral tests and chose milder Pigo A-line mice for behavioral tests. Their body weight was similar among the different genotypes (Supplementary Fig. 9a). Pigo\textsuperscript{a/a} mice had no apparent muscle weakness, whereas Pigo\textsuperscript{b/b} mice showed severe defects in motor function such as balance and coordination in the rotarod test and the four-limb hanging test (Supplementary Fig. 9b–d). In the novel object recognition test, only male wild-type mice spent more time exploring the novel objects than the familiar ones, which means that their memory was functioning normally, whereas Pigo\textsuperscript{a/a} and Pigo\textsuperscript{b/b} mice showed poor cognitive function (Supplementary Fig. 9e).

**Development of novel gene therapy method for IGD.** As the above results indicated that Pigo\textsuperscript{b/b} and Pigo\textsuperscript{b/c} mice had clearly reduced GPI biosynthesis and phenocopied symptoms seen in IGD individuals, we next investigated whether in vivo rescue of GPI biosynthesis ameliorated any of these symptoms. To achieve this, we devised the current HITI method for targeted insertion of Pigo cDNA including the full-coding region and 3' UTRs (a donor sequence) into the 5' UTR of mutant Pigo genes in order to rescue the KI or KO mutations (Fig. 3a). If the targeted insertion occurs as expected, Pigo cDNA would be transcribed under the control of the endogenous Pigo promoter and the Pigo protein would be generated. A donor/gRNA plasmid for the HITI method, termed pAAV-mPigoHITIgRNA, contained a donor sequence sandwiched by inverted gRNA target sequences, and a guide RNA cassette (Fig. 3a). Cas9 expression plasmid (pAAV-nEFCas9) and donor/gRNA plasmid (pAAV-mPigoHITIgRNA) were packaged into AAV-PHP.eB and generated AAV-PHP.eB-nEFCas9 and AAV-PHP.eB-mPigoHITIgRNA viruses, respectively. AAV-PHP.eB is the capsid variant of AAV9, which can efficiently transduce the central nervous system via systemic administration\textsuperscript{38}.

In addition to Pigo expression from the inserted Pigo cDNA (Fig. 3a, bottom), we expected Pigo expression from extra-chromosomally maintained donor/gRNA AAV (AAV-PHP.eB-mPigoHITIgRNA) because the donor construct included the full-coding Pigo cDNA and it would be driven by weak promoter activity in the ITR region of the AAV vector\textsuperscript{35} (Fig. 3a, top). To test this possibility, pAAV-mPigoHITIgRNA was transfected into the PIGO-KO HEK293 cells by lipofection, followed by flow cytometry of CD59, a GPI-AP. The donor plasmid (pAAV-mPigoHITIgRNA) alone restored the surface expression of CD59 in PIGO-KO HEK293 cells, although the expression level was lower than that of a positive control, pMEpuro-mPigo, SRa promoter-driven Pigo cDNA (Fig. 3b). Injection of the donor AAV alone also restored the surface expression of CD59 in PIGO-
KO HEK293 cells, suggesting the weak ITR-driven expression of the full-length Pigo cDNA (Fig. 3c). We next compared promoter activities of AAV ITR and the endogenous Pigo. NIH3T3 cells were infected at various MOI with AAV-PHP.eB bearing nEF promoter-driven EGFP to measure the infection efficiencies by flow cytometry (Supplementary Fig. 10a, b). In parallel, NIH3T3 cells were infected at various MOI with donor AAV. The Pigo mRNA levels were determined by RT-qPCR (Supplementary Fig. 10c) and Pigo gene copy numbers in the infected cells were also determined by qPCR (Supplementary Fig. 10d). When the cells were infected with MOI 10³, Pigo expression was comparable to endogenous level with 14.4% of cells infected. Increase of Pigo expression and Pigo gene copy number from non-infected cells corresponds the viral derived expression and gene copy number.
Fig. 3 Effect of HITI-TE method in vitro. a Schematic view of HITI-TE. (Top) The donor vector, pAAV-mPigoHITIgRNA, containing U6 promoter-driven gRNA (light blue box) and Pigo cDNA (light beige boxes, 5′ and 3′ UTRs; green box, coding region) sandwiched by inverted gRNA target sequences (blue pentagons); thick arrows, vector arms. (Middle) A part of mutant Pigo gene. White and gray boxes, 5′UTR and coding region in exons, respectively; thin lines, upstream regulatory region and introns; red X, a mutation; blue pentagon, the gRNA target sequence; red straight arrow, Cas9 cleavage site. (Bottom) The targeted mutant Pigo gene. Cas9 induced double strand breaks in the target site within the mutant gene and the inverted target sites in the donor vector. After repair, the functional Pigo cDNA was inserted into the target site in a Cas9/gRNA-resistant manner. b Restoration of GPI-anchored protein expression after transfection with pAAV-mPigoHITIgRNA (pAAV-mPigoHITI) donor into Pigo-KO HEK293 cells. Two days later, CD59 expression was analyzed by flow cytometry. Representative data from three independent experiments. c Left panel, restoration of GPI-anchored protein expression after infection with AAV-PHP.eB-mPigoHITIgRNA into Pigo-KO HEK293 cells. Two days later, CD59 expression was analyzed by flow cytometry. Right panel, EGFP expression showing transduction efficiency. Representative data from two independent experiments. d FACs analysis of the restored expression of CD24, a GPI-AP, on the Pigo- knockout Neuro2a by gene editing. Pigo-knockout Neuro2a were transfected with pAAV-nEFCas9 (pAAV-Cas9) and pAAV-mPigoHITIgRNA by lipofection. Two days later, cells were analyzed by FACs. e Validation of correct genome editing by genomic PCR in the i in the Neuro2a cells shown in (d). The scheme of PCR is shown in Supplementary Fig. 12a. Asterisk shows a non-specific band. This result is a representative data of at least three times repeated experiments. f Sequencing analysis of 5′ junction († in a) and 3′junction (‡ in a) of the integration sites in the transfected Neuro2a cells.

respectively. Virus derived Pigo mRNA level per viral gene was about 1%~5% of endogenous level (0.82/0.24 vs 1/0.003 at MOI 103), suggesting that many virus don’t express Pigo or ITR promoter activity is much lower in NIH3T3 cells.

We next compared the AAV ITR-driven Pigo expression with the endogenous Pigo expression in the mouse brain. 1.0 × 10^11 genome copies (GCs) of AAV donor was administered via intravenous injection into newborn wild-type mice. Two weeks after injection with AAV donor, treated mice and non-treated control mice were sacrificed and whole brains were taken. RNA and genomic DNA were isolated from the cerebrum and the relative copy number of ITR-driven Pigo mRNA per gene was compared with that of endogenous Pigo mRNA per gene (Supplementary Fig. 11a-e). Relative ITR-driven expression per gene was similar to endogenous Pigo expression per gene, suggesting that the viral derived Pigo expression was comparable to the endogenous level in the cerebrum (Supplementary Fig. 11c, e).

These lines of evidence suggest that wild-type Pigo would be expressed from both on-target integrated Pigo cDNA and the extra-chromosomally maintained donor AAV, and we termed this combinational approach homology-independent targeted integration assisted by a low level of transgene expression (HITI-TE) (Fig. 3a).

To confirm that the HITI-TE system works properly, pAAV-mPigoHITIgRNA co-transfected with a Cas9 expression plasmid (pAAV-nEFCas9) into Pigo-KO Neuro2a cells by lipofection. The expression of CD24, a GPI-AP, was restored in 19.6% of cells (Fig. 3d). PCR and Sanger sequencing results showed that the transgene was correctly inserted at the target sites within the 5′ UTR, in association with extra small indels (Fig. 3e, f).

Therapeutic ability of HITI-TE for Pigo^b/b^ and Pigo^b/-^ mice. A single dose of 1.0 × 10^11 genome copies (GCs) of each of AAV-PHP.eB-nEFCas9 and AAV-PHP.eB-mPigoHITIgRNA was administered via intravenous injection into newborn Pigo^b/b^ and Pigo^b/-^ mice. At 4 months of age, the levels of Gr-1 on blood granulocytes from HITI-TE-treated Pigo^b/b^ and Pigo^b/-^ mice increased by 22 and 21% compared with those on granulocytes from untreated Pigo^b/b^ and Pigo^b/-^ mice, respectively (Fig. 4a). The plasma ALP level was significantly decreased in HITI-TE-treated Pigo^b/-^ mice at 4 months of age (Fig. 4b, right, p < 0.01). It also tended to be decreased in the treated Pigo^b/-^ mice (Fig. 4b, left). These results suggested that HITI-TE treatment increased GPI biosynthesis.

The body weight of untreated and treated mice was tracked weekly until 24 weeks of age or until death (Fig. 4c). HITI-TE treatment rescued the growth defect in both male and female Pigo^b/b^ or Pigo^b/-^ mice. Especially in males, the HITI-TE-treated Pigo^b/b^ mice were significantly heavier than the untreated mice and were even similar to wild-type mice until 24 weeks of age (Fig. 4c, d).

All untreated Pigo^b/b^ mice exhibited hindlimb clamping, whereas none of HITI-TE-treated Pigo^b/b^ mice showed hindlimb clamping at four months of age (Fig. 4e). Tremor was significantly milder in treated Pigo^b/b^ mice than in untreated Pigo^b/b^ mice (Fig. 4f). As for the FFP power spectral analysis of EEG, three out of four HITI-TE-treated mice showed the decrease in slow waves with high amplitude (Supplementary Fig. 5b). Apparent spontaneous seizures were not detected during observation and only nonmotor seizures were induced by a low dose (20 mg/kg) of PTZ (score 0–3), suggesting that HITI-TE treatment was effective at reducing the susceptibility of Pigo^b/b^ mice to seizures. The results of the hanging test in HITI-TE-treated Pigo^b/b^ mice showed clear improvements, suggesting that the low muscle strength and/or poor motor coordination were ameliorated (Fig. 4g and Supplementary Movie 3). These results indicate that most of the phenotypes of Pigo^b/b^ mice are reversible when Pigo activity is restored soon after birth, and that the novel HITI-TE therapy is a promising approach for the curative therapy of IGD.

Evaluation of HITI-based knock-in event in vivo. To detect the correctly targeted insertion of ectopic Pigo cDNA (Fig. 5a), genomic DNA was extracted from the brain and liver of HITI-TE-treated and untreated Pigo^b/b^ mice. Genomic PCR to specifically amplify the 5′ and 3′ junctions generated the expected PCR products only from the HITI-TE-treated mouse organs (Fig. 5b and Supplementary Fig. 12b). Sanger sequencing analyses of the PCR products revealed that HITI-mediated targeted gene knock-in occurred in the liver and brain even though the indel efficiency at the 5′ and 3′ junctions varied (Fig. 5c, d and Supplementary Fig. 12c, d). Notably, the correct knock-in event was observed by PCR in the brain (Fig. 5b-d), which suggests that gene correction in the brain can be achieved through intravenous injection using the AAV-PHP.eB-assisted HITI system.

Next, we examined the expression ratio of wild-type Pigo transcript as well as the potential off-target effect of donor DNA and transcription from the extra-chromosomally maintained donor DNA. We used 5′ RACE and sequencing to identify the upstream sequence of exon 1 of Pigo mRNA transcribed from the integrated and nonintegrated donor DNAs in the liver and brain (Fig. 6a). Approximately 7–10% of transcribed products contained a normal exon 1 sequence, indicating that they were derived from the AAV donor (AAV-mPigoHITIgRNA) and were expected to show therapeutic effects (orange and red sections in Fig. 6b). Among them, 60–80% and 30% of the products from the brain and liver mRNAs, respectively, were transcribed from the
The possible products from the correctly integrated \textit{Pigo} cDNA accounted for maximally 2–5% of the total products (red). The products from off-target constructs and/or of trans-splicing events were found only in the sample from the liver (gray), as also shown in a previous report\cite{39}. Transcripts from Neuro2a cells transfected with Cas9 and AAV donor in Fig. 3d were similarly analyzed and 10% of the total products were the correctly integrated \textit{Pigo} cDNA with no products of off-target constructs (Fig. 6b). These lines of evidence suggested that products from both on-target integrated and extra-chromosomal \textit{Pigo} cDNAs contributed to the ameliorated phenotypes of the HITI-TE-treated \textit{Pigo}^{b/b} mice.
Fig. 4 Improvement of GPI-AP biosynthesis and the phenotypes in Pigob/b and Pigo/b−/− mice after gene therapy. a Elevation of Gr-1, a GPI-AP, levels on blood granulocytes from Pigob/b mice at 4 months after AAV treatment compared to untreated mice. n number of animals; ns not significant. Data are presented as mean values + SEM. (t-test, two-sided). b Amelioration of hyperphosphatasia. (** p < 0.01). Data are presented as mean values + SEM. (t-test, two-sided, P-value, 5.5 × 10−3). c Improved growth in both treated Pigob/b−/− and Pigo/b−/− mice. P-values of Pigob/b−/−: Pigob/b−/−+HITI in males, p < 0.05 in 9–12w, p < 0.01 in 13–18w. P-value of Pigo/b−/− vs Pigob/b−/−+HITI in males, p < 0.05 in 5–16w and p < 0.01 in 8w and 13w, p < 0.001 in 7w; In females, not statistically significant in both genotypes between HITI treated and untreated. Data are presented as mean values + 3D. d Visual comparison of HITI-TE-treated and untreated Pigob/b−/− mouse. e Comparison of hindlimb clasping between HITI-TE-treated and untreated Pigob/b−/− mice. Score 1–5; score 1, the mildest; score 5, the severest; Data are presented as mean values + SD. f Comparison of the latency to fall by the hanging test in HITI-TE-treated and untreated Pigob/b−/− mice. ** p < 0.01; *** p < 0.001 (t-test, two-sided; P-value, KIhomo:KIhomo+AAV, 6.3 × 10−5; KIKO:KIKO + AAV, 1.0 × 10−4) Data are presented as mean values + SEM. Source data are provided as a Source Data file.

Fig. 5 HITI-mediated genome editing via systemic injection in Pigob/b−/− mice. a Schematic representation of the Pigo KI allele b (T130N, c.389 C > A) genome editing by a HITI donor. After genome editing mediated by NHEJ-mediated HITI, the Pigo full-coding cDNA including corrected mutation are inserted in 5′UTR, upstream of mutated exon 1. Blue pentagon, Pigo exon 1 gRNA target sequence in 5′UTR. Red arrow or black line within blue pentagon, Cas9 cleavage site. Red and blue arrows, PCR primers. b Validation of correct genome editing by genomic PCR in the brain (27-week-old mice). Asterisk shows non-specific band. This result is a representative data of at least three times repeated experiments. c Sequencing analyses of 5′ junctions of the integration sites in the brain of HITI-TE-treated Pigob/b−/− mice. d Sequencing analyses of 3′ junctions of the integration sites in the liver and brain of HITI-TE-treated Pigob/b−/− mice.

Possible advantage of HITI-TE in gene therapy for IGD. To further test usefulness of HITI-TE in gene therapy of IGD, we compared the efficiencies of HITI-TE and single administration of AAV donor alone in vitro and in vivo experiments. Pigko-KO Neuro2a cells were transfected with pAAVCas9 and pAAV donor (pAAV-mPigoHITIgRNA) or pAAV donor only, and analyzed by FACs to determine GPI-AP-restored population for 18 days (Fig. 7a). The rescue effect of AAV donor only was clearly seen on day 3 and disappeared within 2 weeks most likely due to the dilution of pAAV donor plasmid by cell proliferation. In contrast, the cells transfected with both pAAVCas9 and pAAV donor stably retained the restored population (20% of total) for 18 days. These restored population had the corrected Pigo gene by HITI system as shown in Fig. 6b. This result strongly suggests the advantage of HITI-mediated integration over ITR-mediated ectopic expression for dividing cells in terms of therapeutic duration of rescued GPI-AP expression.

To test the therapeutic contribution of ITR-dependent Pigo expression in mice, Pigo−/− mice were treated with AAVCas9 and AAV donor (i.e. HITI-TE treated) or treated with AAV donor alone (i.e., ITR-dependent Pigo expression), and their body weights were monitored. In the first 8 to 10 weeks, there were similar ameliorating effects in both groups, however, the body weight of mice treated with AAV donor only tended to decline from 10 – 12 weeks after the treatment (Fig. 7b). Restoration of Gr-1 expression on the granulocytes was significant in HITI-TE treated mice but not in mice treated with AAV donor only (Fig. 7c). Both groups of mice showed significant decrease in plasma ALP level in that a slightly bigger decrease in the mean ALP level was obtained by HITI-TE treatment than by AAV donor only treatment (38% vs 30%) (Fig. 7d). AAV donor only treated Pigo−/− mice showed clearly improved performance in the hanging test with both 5 mm and 11 mm meshes (Fig. 7e) compared with the untreated Pigo−/− mice (data in Fig. 4g).
both tests, HITI-TE treated mice had slightly longer mean hanging time than AAV donor only treated mice (139 s vs 126 s with 5 mm mesh and 180 s vs 134 s with 11 mm mesh) (Fig. 7e). Four out of six mice treated with AAV donor hung unstably during the tests, whereas all the HITI-TE treated mice hung stably and moved around. HITI-TE treatment ameliorated tremor better than AAV donor only treatment in both timing of tremor appearance (HITI-TE, day 8 vs donor only, day 6) and the severity scores (Fig. 7f and Fig. 4f). These results indicate that both HITI-mediated integration and ITR-driven transient expression of Pigob from the AAV donor contributed to the therapeutic effects with HITI-TE treatment.

Discussion
Here, we describe PIGO-deficient mouse lines harboring three different human mutations. In human cells, Arg119Trp mutant showed the most severe decrease in activity leading to the severest clinical symptoms, such as intractable seizures, severe intellectual disability, and multiple organ anomalies, whereas, in the murine cells, the severest was the Thr130Asn mutant (Supplementary Fig. 1). PIGO makes complex with PIGF, which is critical for PIGO activity. A possible explanation for the difference is that these mutations affect the conformation of PIGO/PIGF complex differently in human and mouse systems. Although the mouse model showed no organ anomalies nor facial dysmorphic features, the neurological symptoms recapitulated the characteristic features of PIGO deficiency. Additionally, brain MRI showed thin corpus callosum and anterior commissure, which mimicked the IGD phenotype. They also showed small pituitary glands, which were previously described in a PIGQ-deficient patient. Ataxic gate and tremor appeared depending on the severity, which suggested cerebellar defects. A known cause of tremor is the loss of Purkinje cells. However, we did not find histological abnormalities of the

Fig. 6 5’ RACE analysis in HITI-TE-treated Pigob/b mice and HITI-TE transfected Neuro2a cells. a Schematics of four or five different origins of Pigob transcripts generated after systemic injection of AAVs for HITI-TE-mediated gene-correction strategy. AAV-mPigoHTgRNA includes a full-coding region of Pigob cDNA and potentially expresses a wild-type Pigob mRNA via a promoter activity of ITR. The on-target integration of the donor via HITI leads to expression of wild-type Pigob mRNA. The off-target integration of the donor captures the transcript of the integration site and express as a fusion gene. Alternatively, trans-splicing between off-target gene and Pigob cDNA also produce a fusion gene. The captured exons including from AAV-derived Pigob, exogenous Pigob and unknown off-target gene were determined with 5’ RACE and sequencing. Blue half-arrows, PCR primers for 5’ RACE. b Percentages of various Pigob transcripts in brain and liver RNAs from HITI-TE-treated Pigob/b mice (#11013; 28 weeks of age, #11762; 27 weeks of age) and HITI-transfected Neuro2a cells in Fig. 3d. Origins of the transcript species: blue, mutant Pigob allele b; orange, wild-type Pigob from the extra-chromosomal AAV donor; red, wild-type Pigob from the corrected genomic Pigob locus; gray, off-target Pigob transcripts or trans-splicing products. Percentages of respective transcript species are indicated. The numbers of sequenced 5’ RACE products (n) are indicated below the charts. Source data are provided as a Source Data file.
**Fig. 7 Effects of single administration of AAV donor in vitro and in vivo.**

a Pigo-KO Neuro2a cells were transfected with pAAVCas9 and pAAV donor (pAAV-mPigoHTlgRNA) or pAAV donor only and analyzed over time by FACS for measuring the restored population. % of CD24 positive cells were shown in the right graph. b Comparison of growth in HITI-treated (AAVCas9 and AAV donor) and AAV donor treated Pigob/b− mice. Data are presented as mean values ± SD. c Elevation of Gr-1, a GPI-AP, levels on blood granulocytes from Pigob/b− mice at 4 months after HITI-treated or AAV donor treated Pigob/b− mice. Data are presented as mean values ± SEM. d Amelioration of hyperphosphatasia. (∗p < 0.05; ∗∗p < 0.01) Data are presented as mean values ± SEM. e Improved performance in the hanging test with 5 mm (left) and 11 mm (right) meshes of AAV donor only treated Pigob/b− mice in comparison with HITI-treated Pigob/b− mice. Data are presented as mean values ± SEM. f Severity scores of tremor appeared in AAV donor only treated Pigob/b− mice and HITI treated Pigob/b− mice at five months (t-test, one-sided, P-value, 0.034). Data are presented as mean values ± SEM. Source data are provided as a Source Data file.
cerebellum even in Pigo<sup>b/b</sup> mice (Supplementary Fig. 7a). Many kinds of GPI-AP are expressed in the central and peripheral nervous systems. For example, ephrin-A, semaphorin-7A, netrin-Gs, glypicans, and contactins play roles in axon outgrowth and navigation, whereas Nogo receptors, MAM domain-containing GPI-APs, T-cadherin, and GFRA1 regulate synaptic function and plasticity<sup>43</sup>. As our model mice had partial deficiency of GPI biosynthesis, these GPI-APs might be decreased to various levels. In fact, Thy1 was decreased by 40 to 50%, whereas contactin1 was not at all decreased even in the Pigo<sup>b/b</sup> mice with the severest phenotypes (Supplementary Fig. 4). It is currently difficult to speculate on which GPI-AP is responsible for the phenotype. At the cellular level, primary neuron culture from the Pigo<sup>b/b</sup> embryo did not show any defect in neurite outgrowth or synapse numbers. In addition, the embryonic fibroblasts derived from the Pigo<sup>b/b</sup> mouse showed no decrease in GPI-AP expression (Supplementary Fig. 8).

At present, no fundamental treatment for IGD is available and the inherent monogenic nature of IGD raises the indication of gene therapy. To establish an effective treatment method for IGD, we have developed AAV-based gene therapy with genome editing by the HITI method, which allows efficient editing of the target gene even in nondividing cells like neurons<sup>33</sup> and lifelong effects. In case of our disease model, as the missense mutation was located in the first exon, we had to take the strategy of the target insertion of full-coding Pigo cDNA into the 5′UTR of the Pigo gene. It should be safe even if it causes indels at the target site and can achieve an endogenous expression level because the inserted Pigo cDNA will be regulated by the endogenous promoter and the regulatory system. Therapeutic effect was not solely by HITI-mediated integration but also by the extra-chromosomal AAV donor containing full Pigo cDNA because the ITR region of the AAV vector possesses weak promoter activity<sup>35</sup>. Indeed, the promoter activity of the ITR was comparable to the endogenous Pigo promoter activity in AAV donor treated mouse brain in vivo (Supplementary Fig. 11). Genomic PCR and DNA sequencing analysis of the tissues from HITI-TE-treated Pigo<sup>b/b</sup> mice revealed that the transgene was integrated in the desired genomic location, although the knock-in efficiency was ~3% at maximum in brain and ~5% in liver (Fig. 6b). Analysis of the transgene integration site by 5′ RACE also revealed that sequences of the AAV vector backbone were amplified, suggesting that Pigo cDNA from the extra-chromosomal AAV donor was expressed. As the Pigo cDNA-containing AAV donor vector alone could rescue the GPI-AP expression on Pigo-KO HEK293 cells when a high copy number was introduced (Fig. 3b, c), ITR-driven Pigo cDNA might contribute to improving the phenotypes in vivo<sup>35</sup>. To examine its contribution, we treated Pigo<sup>b/b</sup>/ mice only with AAV donor, which allows ITR-driven Pigo expression. Whereas the treatment with AAV donor only did not significantly increase Gr-1 on blood granulocytes (Fig. 7c), it reduced serum ALP levels (Fig. 7d). In the first 8–10 weeks, AAV donor only treatment had ameliorating effect on body weight similar to the HITI-TE treatment, however, the body weight of mice treated with AAV donor only tended to decline after 10 – 12 weeks of age (Fig. 7b). Therefore, ITR-driven Pigo expression from the AAV donor had therapeutic effects in mice. In summary, the combination of gene editing and an extra-chromosomal transgene appears to be effective to treat the IGD model mice. The same combination therapy could be designed including a promoter upstream to the sgRNA sites to sustain higher level of the transgene while enabling HITI-mediated gene repair, however we wanted to have a low Pigo expression in order not to affect balance between Pigo and Pigg. Pigo and Pigg are individually complexed with Pigf and mediate EthN-P transfers to Man3 and Man2, respectively. It was shown previously that PIGO overexpression affected PIGG enzyme level by interfering generation of PIGG and PIGF complex<sup>31</sup>. Recently, it became clear that too much expression of transgene is harmful in gene therapy, causing liver dysfunction and thrombocytopenia. Clinicians are trying to regulate the expression using drug inducible constructs. As ITR-driven expression of Pigo is at a similar level to endogenous expression, it would be a reasonable choice in combination with gene editing therapy. Further analysis is required to investigate whether our combined strategy has an advantage over conventional gene transfer, even if it has a risk of off-target effects. In fact, off-target effects could be detected in 9% of liver transcripts analyzed by 5′ RACE.

It is interesting that the neurological phenotype of HITI-TE-treated Pigo<sup>b/b</sup> mice was clearly improved despite the low efficiency of precise genome editing, which was lower than 10%. Similar findings were reported in previous papers, showing that low gene correction efficiency was sufficient to improve the phenotypic outcomes<sup>33</sup>. The authors explained that an indirect non-cell autonomous effect from the small number of gene-corrected cells in the tissue improved the phenotype. There are several lines of evidence published showing that GPI-anchored proteins (GPI-APs) are transferred to the other cells. GPI-APs expressed on the surface of transgenic mouse red blood cells were transferred in a functional form to endothelial cells in vivo<sup>44</sup>. Piga<sup>−/−</sup> embryonic bodies (EB) produced no secondary hematopoietic colonies, however, in the chimeric EB composed with normal cells and Piga<sup>−/−</sup> cells, hematopoiesis from knock-out cells was reconstituted due to transfer of GPI-APs from normal to knock-out cells<sup>45</sup>. GPI-APs are efficiently sorted in exosomes and are transferred to the other cells<sup>46,47</sup>. According to these lines of evidence, GPI-APs transfer from the gene-corrected cells might contribute to the phenotype improvement. Restoration of Gr-1 on granulocytes was seen at 4 months after the HITI-TE-treatment, suggesting the gene-editing event in hematopoietic progenitor cells.

Our results proved that gene therapy for IGD is a potential therapeutic strategy. They also suggested that the symptoms of IGD are reversible if treated at a young age. To further promote the practical use of this approach, there is a need to develop optimized gene therapy for humans. AAV-PHP.eB can penetrate diffusely into the mouse brain even in adults, but only for limited strains<sup>48,49</sup>, while it does not work in humans. Recently, Ly6A has been reported as an endothelial receptor that allows AAV-PHP.eB to cross the blood–brain barrier (BBB)<sup>49,50</sup>. The lymphocyte antigen-6 (Ly6)/urokinase-type plasminogen activator receptor (uPAR) family members, respectively, but there is no ortholog of Pigo in the human genome. Pigo KO mice are expected to express less Ly6A than wild-type mice and are at a disadvantage for AAV-PHP.eB treatment. The expression levels of Ly6A were also found to be lower in newborn mice than in adult mice<sup>51</sup>. Nevertheless, there was a clear phenotypic improvement, suggesting that the expression level of Ly6A in the affected newborn mice was sufficient for the virus to cross the BBB. The human and mouse genomes contain 35 and 61 Ly6/uPAR family members, respectively, but there is no ortholog of Ly6A in primates<sup>52</sup>. Other Ly6 proteins expressed on the endothelium of the primate central nervous system can be candidate receptors. Developing capsids that bind to these receptors should open the way for efficient gene therapy of various inherited neurological diseases.

**Methods**

**Functional analysis of the Pigo mutant cDNAs in the mouse cells.** Clones of Pigo-knockout (KO) Neuro2a, a mouse neuroblastoma cell line, were generated by CRISPR–Cas9 system. Each Pigo mutant cDNA (R119W, T130N, K1051E) derived by a strong promoter, Ska, was transfected into Pigo-KO Neuro2a cells by Lipofectamin 2000 (Invitrogen) together with luciferase expressing plasmid for the transfection control. Two days later, cells were stained with FLAER (fluorescent-labeled inactive toxin aerylosin, CEDARLANE), which reacts with GPI-APs, or PE.
labeled anti-CD24 antibody (Biolegend) and were analyzed by flow cytometry (MACSQuant Analyzer; Miltenyi Biotech) with FlowJo software (Tommy Digital). Lysates of these transfectants were subjected to SDS-PAGE and immunoblotting for HA tag. For quantification, relative protein expression was determined by dividing HA-Pigo band intensities (detected by rabbit monoclonal anti-HA, 1:2000 dilution, #2178, Cell Signaling) by those of GAPDH (detected by mouse monoclonal anti-GAPDH, 1:2000 dilution, AM4300, Invitrogen) and by Luciferase activity to normalize for both loading and transfection efficiencies and resulting values converted to make the wild-type value as 1.

**Animal generation.** Three lines of KI ES cells bearing Pigo mutations (A-line, R119W; B-line, T130N; C-line, K1051E) were established using CRISPR-Cas9 system (Supplementary Fig. 2). In brief, C57BL/6 derived ES cells were co-transfected with px459 vector (Addgene) containing a target gRNA sequence (AACGCCCATGACCAGCTC for A-line, GCCGTACCCATCT-CAGGTGG for B-line, AAGTATGTTGCTTCCGTGA for C-line) and a donor plasmid containing a 1.5 kb homologous region for efficient target recombination, which includes a pathogenic mutation (c.355 G > T in nucleotide sequence for A-line, c.389 C > A for B-line, and c.351A > G for C-line), with silent one-base substitution mutation to prevent recombination and cleavage, and an restriction enzyme site for easy genotyping. (Sall site for A- and B-line for, FspI site for C-line). Successful KI ES cells were picked. Three lines of mice were generated according to the usual method using these KI ES cells bearing A, B, or C-line mutation. An ES clone bearing a Pigo-KO allele was accidentally generated during A-line KI process due to a homologous recombination failure. The KO allele contains a repeated exon 1 with intervening sequences, which is transcribed to tandemly connected exon 1, generating a premature termination codon, leading to nonsense mediated decay.

**Animals.** All mice were C57BL/6 background and maintained in SPF under a 12 h light/12 h dark cycle with food and water provided ad libitum. Temperature and humidity were within the recommended range (20 – 24° and 40 – 60%, respectively). All animal procedures were approved by the Animal Care and Use Committee of the Research Institute for Microbial Diseases, Osaka University, Japan. The methods were carried out in accordance with the approved guidelines. Pigo heterozygous KI mice and KO mice were maintained by mating with C57BL/6 mice.

**Genotyping.** The Pigo A- and B-line KI mice were genotyped by polymerase chain reaction (PCR) using Primestar GLX DNA polymerase (Takara bio) with the primers 5′ TTGACCAGCTGGAATATTGG3′ (primer 1) and 5′ TAGAGGTGGTCCCAAGATGCCG3′ (primer 2). Then, PCR products were digested with Sall-HF (New England Biolabs) and separated on a 1% agarose gel. KI alleles were detected by the digested PCR product bands of 1021 bp and 761 bp. The Pigo C-line KI mice were also genotyped by PCR with the primers 5′ CGGGCTCAAGGTTCTTCTAC3′ (primer 3) and 5′ GAAAACA-TAGTGCTTCAAACTGCCG3′ (primer 4), followed by digestion with FspI (New England Biolabs). KI alleles were detected by the digested PCR product bands of 831 bp and 395 bp. A single allele was detected by FspI PCR with the primer 1 and the primer 5′ GAAAGGACGGCGCTAGGG3′ (primer 5), followed by digestion with Sall-HF, generating the bands of 878 bp and 761 bp.

**Measuring alkaline phosphatase (ALP) activity.** Whole blood was collected from the mouse tail tip, and plasma was separated by centrifugation. ALP activity in plasma was measured in the clinical laboratory by the JSCC recommended method using p-Nitrophenylphosphate (pNPP) as a substrate. As ALP activity is high at an early age, mice older than 4 months were investigated. Mice were anesthetized with isoflurane and bregma, 2 mm lateral to midline; occipital: 2 mm anterior to lambda, 2 mm lateral to midline. The heads were held in place with dental cement. After the cement set, the electrodes were attached to thin cables linked to a computer running software, allowing visualization of the EEG activity with simultaneous video recording (Vital Recorder, Kissie Comte). Video EEGs were recorded overnight, and the files were reviewed for background activity, epileptic discharge, and seizure activity (SleepSign, Kissie Comte). Additionally, dose of pentylenetetrazole (PTZ) (20 mg/kg) was administered intraperitoneally, and video EEGs were recorded for 2 h to evaluate PTZ-induced seizure susceptibility using Modified Racine scale37. Frequency and amplitude of 8 h recording EEG data were calculated by Fast Fourier transform (FFT) power spectral analysis33. Data were analyzed in 10-s epochs by the SleepSign software. The EEG signal was separated into five regions per epoch. Each region was fitted calculated by using 256 datum points (2 s) before the five spectra were averaged. The spectrum has the resolution of 0.5 Hz.

**Magnetic resonance imaging.** In vivo magnetic resonance imaging (MRI) of mice were conducted using an 11.7 T vertical bore scanner (AVANCE II 500WB; Bruker BioSpin, Ettlingen, Germany). Two males and one female of Pigo mice (15 weeks) were used. Pigo heterozygous KI littermates of each male and female mice were also used for comparison (two males and one female). Anesthesia of mice was initially induced with 2% isoflurane and maintained with 1.6% isoflurane during MRI. Body temperatures of mice were maintained at 37 °C with circulating warm water. T1- weighted images were obtained by the Rapid Acquisition with Relaxation Enhancement (RARE) technique38. Acquisition parameters were as follows: field of view (FOV) = 20 mm × 20 mm, matrix size = 256 × 256, in plane resolution = 78 μm, slice thickness = 300 μm, repetition time (TR) = 6000 ms, echo time (TE) = 37.6 ms, number of averages [NA] = 12, acquisition time = 19 min.

**Western blotting.** The brains of adult mice at 4 months of age were taken after perfusion with saline, homogenized and solubilized with 60 ml of n-octyl-β-D-glucoside containing lysis buffer, followed by centrifugation to remove the debris. After centrifugation, the protein amount was determined by the Coomassie blue method, and the protein was subjected to PAGE followed by western blotting. Primary antibodies used for the assay were goat anti-human contactin1 (1:1000 dilution, AP904, R&D systems), rat monoclonal anti-mouse Thy1 (1:300 dilution, 105202, G7, Bio-legend), rat monoclonal anti-MBP (1:3000 dilution, clone12, MCA409S, Bio-Rad), and mouse monoclonal anti-GAPDH (1:2000 dilution, AM4300, Invitrogen). Secondary antibodies were used: HRP-conjugated anti-goat or rat or mouse IgG-HRP.

**Histological analysis of the mouse brain.** The mice at 4 months of age were deeply anesthetized with isoflurane and transcardially perfused with 20 ml of PBS/1% heparin followed by 10 ml of 4% paraformaldehyde (PFA)/PBS. The brains were taken and fixed in 4% PFA/PBS in 4 °C for an overnight and brains were washed in PBS. For paraffin-embedded sections, brains were cut on a vibratome in 50 and 70% ethanol and xylene and then stained with Thionin according to the usual method using p-Nitrophenylphosphate (pNPP) as a substrate. For immunohistochemical staining, sections on the slide glasses were dried up for 30 min and digested with 40% formic acid for 10 min. These brain sections were washed in PBS and incubated in 300 μl of Hanks solution on a roller mixer. The brains of adult mice at 4 months of age were taken after perfusion with saline, homogenized and solubilized with 60 ml of n-octyl-β-D-glucoside containing lysis buffer, followed by centrifugation to remove the debris. After centrifugation, the protein amount was determined by the Coomassie blue method, and the protein was subjected to PAGE followed by western blotting. Primary antibodies used for the assay were goat anti-human contactin1 (1:1000 dilution, AP904, R&D systems), rat monoclonal anti-mouse Thy1 (1:300 dilution, 105202, G7, Bio-legend), rat monoclonal anti-MBP (1:3000 dilution, clone12, MCA409S, Bio-Rad), and mouse monoclonal anti-GAPDH (1:2000 dilution, AM4300, Invitrogen). Secondary antibodies were used: HRP-conjugated anti-goat or rat or mouse IgG-HRP.

**Culturing primary neurons from mouse hippocampus.** Adult mice at 4 months of age or older were used for all EEG recordings. The mice were anesthetized with isoflurane and implanted with EEG electrodes (Pinnacle 8201; 2 EEG/1 EMG Mouse Headmount) according to the manufacturer’s instructions. Electrodes for these EEG recordings were positioned over the frontal and occipital cortex (frontal: 2 mm anterior to bregma, 2 mm lateral to midline; occipital: 2 mm anterior to lambda, 2 mm lateral to midline). The heads were held in place with dental cement. After the cement set, the electrodes were attached to thin cables linked to a computer running software, allowing visualization of the EEG activity with simultaneous video recording (Vital Recorder, Kissie Comte). Video EEGs were recorded overnight, and the files were reviewed for background activity, epileptic discharge, and seizure activity (SleepSign, Kissie Comte). Additionally, dose of pentylenetetrazole (PTZ) (20 mg/kg) was administered intraperitoneally, and video EEGs were recorded for 2 h to evaluate PTZ-induced seizure susceptibility using Modified Racine scale37. Frequency and amplitude of 8 h recording EEG data were calculated by Fast Fourier transform (FFT) power spectral analysis33. Data were analyzed in 10-s epochs by the SleepSign software. The EEG signal was separated into five regions per epoch. Each region was fitted calculated by using 256 datum points (2 s) before the five spectra were averaged. The spectrum has the resolution of 0.5 Hz.
(17504-044, Life technologies) and Glutamax (35050-061, Invitrogen). Cells were seeded in the poly-L-lysine coated 96 well plates (1.0 x 10^4 cells/100ul/well MS-0096, SUMITOMO) and 5% FBS and day 7, cells were fixed with 4% PFA for 15 min at room temperature, washed with PBS, permeabilized with 0.25% Triton-X100 for 5 min at room temperature, washed with PBS three times and then, incubated with blocking buffer (Nakara) for 30 min at room temperature. Cells were incubated with the first antibody for overnight at 4℃, washed with PBS and incubated with the second antibody for 2 h at room temperature. After washed with PBS, cells were analyzed with confocal microscope, Opera LX (PerkinElmer). The first antibodies, mouse monoclonal anti-Nestin (1:300 dilution, Rat-601, ab6142, Abcam), rabbit polyclonal anti-β-tubulin (Tuj1) (1:2000 dilution, ab18207, Abcam), chicken polyclonal anti-MAP2 (1:5000 dilution, ab5392, Abcam), rabbit polyclonal anti-NeuN (136E, ab177487, Abcam), guinea pig polyclonal anti-Synapsin 1 (1:1000 dilution, 106 004, Synaptic systems), mouse monoclonal anti-Tau-1 (1:500 dilution, PC1C6, MA34320, Chemicon); the second antibodies, goat anti-mouse IgG- Alexa488 (1:500 dilution, A11029, Life Technologies), goat anti-chicken IgY- Alexa555 (1:500 dilution, A2392, Life Technologies), goat anti-rabbit Alexa647 (1:500 dilution, A22283, Life Technologies), goat anti-guinea pig IgG-Alexa488 (1:500 dilution, A-11073, Life Technologies).

Animal behavioral analysis. Total of 17 male and 19 female of Pigo A-line mice (5–9 months of age) were sent to the animal facility of Asubio Pharma Co., Ltd. and behavioral tests were performed.

Rotated tests were performed to assess motor coordination and balance. The subject mice were trained for 2 min at 4 rpm and then tested on the accelerated setting (4–40 rpm, 5 min) two times, and the average of the latency to fall was recorded.

Novel object recognition test was performed in the square chamber to test learning and memory in mice. It consists of three sessions, one habituation session, one training session which involves visual examination of two identical objects for 1-2 min each other, and finally a test session, which involves replacing one of the previously explored objects with a novel object. The use of each set of object is counterbalanced so that each object is used equally as a familiar object and as a novel object. Because mice have an innate preference for novelty, a mouse that remembers the familiar object will spend more time exploring the novel object. Using Video tracking system (ANY- maze version 1.0, Stoelting Co.), the movement and the behavior of the mice were monitored with a video camera. Muscle weakness and coordination deficit were measured by four limb-hanging test. The latency to fall was recorded with a 300 s cut-off time. The distance traveled by the mouse before falling off the grids was also recorded using video tracking system. The performance of the mutants was compared with that of wild-type controls.

As for Pigo B-line mice treated with AAV, we assessed the severity of tremor using a five-score scale (Supplementary Movie 2), and four-limb hanging test (5 mm and 11 mm mesh) was performed at 5 months of age to demonstrate neuromuscular impairment and motor coordination. Tremor was analyzed weekly, and the severity of tremor was evaluated using a five-score scale by one observer, and the score was checked by another observer by watching video.

Generation of genome editing AAV plasmids. AAV-neEFAc9 plasmid was purchased from Addgene (#87115). To construct a donor/gRNA AAV for HITI, donor DNA was exchanged with Cas9/gRNA target sequences and a gRNA expression vector with Zero Blunt TOPO cloning kit (#450245, Invitrogen). Amplicons were sequenced using an ABI 3730xl sequencer (Applied Biosystems).

Intravenous AAV injection to newborn Pigo deficiency mouse model. The newborn (P1–P3) B-line homozygous KI or KIKO mice were subjected to intravenous AAV injection as in a previous report. Prior to procedure pups were incubated on ice for 1 min to anaesthetize and subsequently injected via the temporal cavity using a 30 G insulin needle (BD lo-dose Insulin syringe with needle, 30 G, 1/2 ml). Then, the pups were given 2–5 mm to warm-up and recover and returned to the cage.

Evaluation of in vivo HITI-mediated knock-in event by Sanger sequence, genomic DNA from brain and liver was extracted and the HITI-mediated gene knock-in locus was amplified in the same way as mentioned above. The 5′ junction site was amplified by PCR with following HITI-specific primers in liver: mPigoHITIS5′-F and mPigoHITIS1′-R were used. The 5′ junction site was amplified by nested PCR with following HITI-specific primers in brain. For 1st PCR, mPigoHITIS5′-F and mPigoHITIS1′-R were used. For 2nd PCR, mPigoHITIS5′-F2 (5′-GCACTCCGAACCCGGTCCAGTGTC-3′) and mPigoHITIS1′-R2 (5′-CACATCCCAAGACGCCCGTGAGT-5′) were used (Supplementary Table 2). The 3′ junction site was amplified by PCR with following first-hit primers: mPigoHITIS1′-F and mPigoHITIS5′-R. PCR products were cloned into the pCR-Blunt II-TOPO vector with Zero Blunt TOPO cloning kit (#450245, Invitrogen). Amplicons were sequenced using an ABI 3730xl sequencer (Applied Biosystems).

5 RACE-based off-target and transcript analyses. SMARTer RACE 5′/3′ Kit (#634888, Takara Bio USA, Inc.) was used for performing the 5′ rapid amplification of cDNA ends (5′RACE) according to manufacturer’s instructions. 1 μg total RNA was used for this reaction. Pigo exon 2/3 junction-specific primer used in this experiment was 5′-GATTACGCGAAGTCTGTCCCAGCCCGTCCAGTG-3′ (primer 10) for 1st PCR. PCR products were cloned into the In-Fusion HD Cloning Kit. RACE fragments were sequenced using an ABI 3730xl sequencer. The captured exons which are located up to upstream of Pigo exon 1 were mapped on UCSC mouse genome browser (NCBI/ mm9) (https://genome.ucsc.edu/cgi-bin/hgGateway?db=mm9).

Analysis of promoter activity of ITR which drives Pigo in AAV donor. Piko-HKO293 cells were transfected with an AAV donor plasmid (pAAV-PHP.eB-mPigoHITIgRNA) or a strong promoter (Shs) driven mPigo (pME-mPigo) by Lipofectamine 2000 (Invitrogen). They were also infected with AAV donor or AAV neEFGP at 100 K MOI in the serum free medium, pretreated with 100 μM of neuromodulin. After 24 h, the serum free medium was changed to medium containing 10% FCS. Two days later, cells were stained with anti-CD39 (5H), fol- lowed by PE labeled anti-mouse IgG and were analyzed by flow cytometry (MACSQuant Analyzer; Miltenyi Biotec) with Flowjo software (Trelo Health). 2 x 10^5owell of NIH3T3 cells, derived from a murine embryo fibroblast cell line, were plated in the 12 well plate. On the next day, they were pretreated with 100 μM of neuromodulin in the serum free medium for 2 h at 37℃, after which the serum free medium cells were infected with AAV-PHP-eB-neEFGP or AAV donor (AAV-PHP-eB-mPigoHITIgRNA). After 48 h from infection, cells were harvested, FACS analysis was performed for AAV-PHP-eB-neEFGP infected cells, genomic DNA and RNA were isolated from AAV infected cells. Total RNA was reverse transcribed using Superscript First-Strand Synthesis System for Quantitative Real-Time RT-PCR (Invitrogen). qPCR was performed with the cDNA and genomic DNA by SYBR Green PCR master mix (Applied Biosystems) and primers using StepOnePlus Real-Time PCR Systems (Applied Biosystems). Pigo expression was determined by qPCR with the comparative Ct method using the primer GCCAGCCCAACCTGTCGATG (qPCRmPigo-F1) and CACCTGGTGAAGCTGTCG (qPCRmPigo-R1). For endogenous control, primer TATGACCCCTATCACTTCTG (qPCRmEndo-F1) and GATATCTTCTCTCC (qPCRmEndo-R1) were used. Relative RT vs endogenous promoter activities were 0.82/0.24 vs 1/0.003, ie 3.43 vs 333.

For in vivo analysis, wild-type mice (n = 3) were treated with AAV donor on 2 days after birth. Two weeks later, AAV treated mice and non-treated littersates (n = 3) were sacrificed and brains were taken out. Total RNA and genomic DNA were extracted from the kit DNA extraction kit (Qiagen) from the whole cerebrum. Total RNA was reverse transcribed using Superscript VILO kit (Invitrogen) and qPCR were performed with the CDNA and genomic DNA by

**ARTICLE** NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-30847-x | www.nature.com/naturecommunications
SYBR Green PCR master mix (Applied Biosystems) and primers using StepOnePlus Real-Time PCR Systems (Applied Biosystems). Standard curve was made by serial dilutions of AAV donor plasmids in the solution containing Herring sperm DNA (Promega). For qPCR-driven expression, the probe was set in U6 promoter. For endogenous Pigo expression, the probe was set in the Pigo exon boundary (Supplementary Table 2). cDNA copy numbers were normalized with relative Tbp expression as an endogenous control. ITR promoter activity is calculated by U6 cDNA/U6 genome copy numbers, whereas endogenous Pigo promoter activity is calculated by Pigo cDNA copy/Pigo genome copy numbers.

**Data availability**

Full scans for all western blots and raw data are provided in the Supplementary Information. All other data are available from the corresponding author on reasonable request. Source data are provided with this paper.

**Received:** 7 January 2021; **Accepted:** 20 May 2022;

**Published online:** 03 June 2022

**References**

1. UniProt, C. UniProt: a hub for protein information. *Nucleic Acids Res.* **43**, D204–D212 (2015).
2. Kinoshita, T. Biosynthesis and deficiencies of glycosylphosphatidylinositol. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* **90**, 130–143 (2014).
3. Kinoshita, T. Biosynthesis and biology of mammalian GPI-anchored proteins. *Hum. Mol. Genet.* **12**, 846–851 (2006).
4. Kawagoe, K. et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. *Blood* **87**, 3600–3606 (1996).
5. Tremml, G. et al. Increased sensitivity to complement and a decreased red blood cell life span in mice for a nonfunctional Piga gene. *Blood* **94**, 2945–2954 (1999).
6. Kuki, I. et al. Vitamin B6-responsive epilepsy due to inherited GPI deficiency. *Neurology* **81**, 1467–1469 (2013).
7. Nakamura, K. et al. PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels. *Epilepsia* **55**, e13–e17 (2014).
8. Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *Nature Med.* **20**, 1713–1722 (2017).
9. Koijma, K. et al. Gene therapy improves motor and mental function of aromatic L-amino acid decarboxylase deficiency. *Brain* **142**, 322–333 (2019).
10. Nagao, M., Tomkowicz, B., Perry, W. L., Strahl, W. R. Adeno-Associated Virus (AAV) as a vector for gene therapy. *BioDrugs* **31**, 317–334 (2017).
11. Ronzitti, G., Gross, D. A. & Mingozi, F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. *Front. Immunol.* **11**, 670 (2020).
12. Shishioh, N. et al. GPI7 is the second partner of PIG-F and involved in modification of glycosylphosphatidylinositol. *J. Biol. Chem.* **280**, 9728–9734 (2005).
13. Hasselt, N. & Durocher, D. The control of DNA repair by the cell cycle. *Nat. Cell Biol.* **19**, 1–9 (2016).
14. Suzuki, K. et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. *Nature* **540**, 144–149 (2016).
15. Flotte, T. R. et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. *J. Biol. Chem.* **268**, 3781–3790 (1993).
16. Haberman, R. P., McCown, T. J. & Samulski, R. J. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. *J. Virol.* **74**, 8732–8739 (2000).
17. Zehavi, Y. et al. A homozygous PIGO mutation associated with severe infantile epileptic encephalopathy and corpus callosum hypoplasia, but normal alkaline phosphatase levels. *Nat. Med.* **22**, 1213–1217 (2016).
18. Van Erum, J., Van Dam, D., De Deyn, P. P. PTZ-induced seizures in mice require a revised Racine scale. *Epilepsy Behav.* **95**, 51–55 (2019).
19. Chan, Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat. Neurosci.* **20**, 1172–1179 (2017).
20. Suzuki, K. et al. Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction. *Cell Rep.* **29**, 804–819 (2019).
21. Johnstone, D. L. et al. Early infantile epileptic encephalopathy due to bi-allelic pathogenic variants in PIGQ: Report of 7 new subjects and review of the literature. *J Inherit Metab Dis* (2020).
22. Pan, M. K., Ni, C. L., Wu, Y. C., Li, Y. S. & Kuo, S. H. Animal models of Tremor: relevance to human tremor disorders. *Tremor Other Hyperkinet Mov. (N. Y.)* **8**, 587 (2018).
23. Lukacs, M., Blizard, L. E. & Stottmann, R. W. CNS glycosylphosphatidylinositol deficiency results in delayed white matter development, ataxia and premature death in a novel mouse model. *Hum. Mol. Genet.* **29**, 1205–1217 (2020).
24. Um, J. W. & Ko, J. Neural glycosylphosphatidylinositol-anchored proteins in synaptic specificiation. *Trends Cell Biol.* **27**, 931–945 (2017).
25. Kooyman, D. J. et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. *Science* **269**, 89–92 (1995).
26. Dunn, D. E. et al. A knock-out model of paroxysmal nocturnal hemoglobinuria: Pig α(-) hemotitosis is reconstituted following intercellular transfer of GPI-anchored proteins. *Proc. Natl Acad. Sci. USA* **93**, 7938–7943 (1996).
27. Muller, G. A. The release of glycosylphosphatidylinositol-anchored proteins from the cell surface. *Arch. Biochem. Biophys.* **655**, 1–18 (2018).
47. Vidal, M. Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids. *Adv. Drug Deliv. Rev.* **161–162**, 110–123 (2020).

48. Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL/6j mice. *Mol. Ther.* **26**, 664–668 (2018).

49. Hordeaux, J. et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. *Mol. Ther.* **27**, 912–921 (2019).

50. Huang, Q. et al. Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. *PLoS One* **14**, e0225206 (2019).

51. Silva-Pinheiro, P., Cerutti, R., Luna-Sanchez, M., Zeviani, M. & Viscomi, C. A single intravenous injection of AAV-PHP.B-hNDUFS4 ameliorates the phenotype of Ndufs4 (−/−) mice. *Mol. Ther. Methods Clin. Dev.* **17**, 1071–1078 (2020).

52. Loughner, C. L. et al. Organization, evolution and functions of the human and mouse Ly6/uPAR family genes. *Hum. Genomics* **10**, 10 (2016).

53. Kohtoh, S. et al. Algorithm for sleep scoring in experimental animals based on fast Fourier transform power spectrum analysis of the electroencephalogram. *Sleep. Biol. Rhythms* **6**, 163–171 (2008).

54. Hennig, J., Nauerth, A. & Friedburg, H. RARE imaging: a fast imaging method for clinical MR. *Magn. Reson Med.* **3**, 823–833 (1986).

55. Gombash Lampe, S. E., Kaspar, B. K. & Foust, K. D. Intravenous injections in neonatal mice. *Journal of visualized experiments: JoVE* **1**, e52037 (2014).

**Author contributions**
R.K., T.K., K.O. and Y.M. designed the study. R.K., K.S., J.N., E.A., Y.Y., Y.S., S.N. and Y.M. acquired the data and conducted experiments. M.I. made the knock-in mice. K.I. prepared AAV. R.K., K.O., S.N., K.S., T.K. and Y.M. wrote and edited the paper.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-30847-x.

Correspondence and requests for materials should be addressed to Yoshiko Murakami.

**Peer review information** *Nature Communications* thanks Hudson Freeze and the other anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

**Reprints and permission information** is available at http://www.nature.com/reprints

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Acknowledgements**
We thank Junji Takeda (Osaka University) for discussion, Yoshihiro Tani (Asubio Pharma Co.) for performing mice behavioral analysis, Keiko Kinoshita, Saori Umeshita, Kae Imanishi, Kana Miyamagi (Osaka University), and Maki Fujiwara (Kyoto University) for technical help. We thank Edanz Group (https://en-author-services.edanzgroup.com/) for editing the English text of a draft of this manuscript. This work was supported by JSPS and MEXT KAKENHI grants (IP16h04753 and IP17H06422 for T. Kinoshita), a grant from Ministry of Health, Labor and Welfare (20FC1025) and Mizutani Foundation for Glycoscience, KOSE Cosmetology Research Foundation, the Osaka Medical Research Foundation for Intractable Diseases, a grant from Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED) (21ak01094180003 for Y. Murakami), grants form JSPS KAKENHI (18H04036) and Takeda Science Foundation for K. Suzuki and a grant from AMED/IP20dm0307021 for K. Inoue.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022